cbdMD, Inc.(YCBD)Earnings, Financials & Key Ratios
YCBD•AMEX
$0.83
$8M mkt cap·Price updated May 7, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryCannabis and cannabinoid product companies
AboutcbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.Show more
- Revenue$19M-1.5%
- EBITDA-$367K+73.2%
- Net Income-$2M+44.8%
- EPS (Diluted)-1.09+39.1%
- Gross Margin56.5%-8.2%
- EBITDA Margin-1.91%+72.8%
- Operating Margin-11.27%+31.2%
- Net Margin-10.63%+44.0%
- ROE-44.42%+34.0%
- ROIC-0.41%+99.0%
- Debt/Equity107.70+16550.1%
YCBD Key Insights
cbdMD, Inc. (YCBD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 6.7% through buybacks
- ✓Trading at only 0.5x book value
- ✓Efficient asset utilization: 1.8x turnover
✗Weaknesses
- ✗High debt to equity ratio of 107.7x
- ✗Negative free cash flow
- ✗Sales declining 14.5% over 5 years
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
YCBD Price & Volume
cbdMD, Inc. (YCBD) stock price & volume — 10-year historical chart
Loading chart...
YCBD Growth Metrics
cbdMD, Inc. (YCBD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-14.45%
3 Years-18.46%
TTM26075.44%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-12087.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1011.1%
Return on Capital
10 Years-68.94%
5 Years-20.97%
3 Years-44.59%
Last Year-47.07%
YCBD Peer Comparison
cbdMD, Inc. (YCBD) competitors in Cannabis and cannabinoid product companies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TLRY | 659.52M | 5.66 | -0.17 | 4.84% | -252.55% | -136.55% | 0.22 | |
 CGC | 121.54M | 1.13 | -0.28 | -9.47% | -110.99% | -43.07% | 0.72 | |
 ACB | 194.51M | 3.43 | 164.21 | 27.01% | 11.24% | 7.15% | 0.17 | |
 XXII | 118.79K | 0.71 | -0.01 | 48.06% | -20.53% | -25.03% | 0.27 | |
 BYFC | 91.52M | 9.84 | -3.05 | -3.76% | -9.05% | 0.58 | ||
 HALO | 7.68B | 65.19 | 25.46 | 37.55% | 22.69% | 6.49% | ||
 HIMS | 6.63B | 25.67 | 50.32 | 59% | 5.47% | 23.73% | 2.07 | |
 CRON | 980.69M | 2.57 | 64.4% | -4.89% | -0.86% | 0.00 |
Compare YCBD vs Peers
cbdMD, Inc. (YCBD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
YCBD Income Statement
cbdMD, Inc. (YCBD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 4.47M | 8.42M | 23.65M | 41.88M | 44.48M | 35.4M | 24.16M | 19.48M | 19.19M | 18.77M |
| Revenue Growth % | 120.27% | 88.16% | 180.89% | 77.09% | 6.2% | -20.41% | -31.77% | -19.35% | -1.5% | 26075.44% |
| Cost of Goods Sold | 1.36M | 2.67M | 9.14M | 15.51M | 14.5M | 13.07M | 9.18M | 7.49M | 8.35M | 2.02B |
| COGS % of Revenue | 30.29% | 31.75% | 38.63% | 37.04% | 32.59% | 36.91% | 37.99% | 38.43% | 43.5% | - |
| Gross Profit | 3.12M▲ 0% | 5.75M▲ 84.2% | 14.51M▲ 152.6% | 26.37M▲ 81.7% | 29.99M▲ 13.7% | 22.34M▼ 25.5% | 14.98M▼ 32.9% | 12M▼ 19.9% | 10.84M▼ 9.6% | 3.01B▲ 0% |
| Gross Margin % | 69.71% | 68.25% | 61.37% | 62.96% | 67.41% | 63.09% | 62.01% | 61.57% | 56.5% | 59.8% |
| Gross Profit Growth % | 655.11% | 84.22% | 152.57% | 81.67% | 13.72% | -25.51% | -32.95% | -19.91% | -9.62% | - |
| Operating Expenses | 3.36M | 5.63M | 28.88M | 43.95M | 49.6M | 39.56M | 37.47M | 15.31M | 13M | 3.3B |
| OpEx % of Revenue | 75.06% | 66.86% | 122.09% | 104.94% | 111.51% | 111.74% | 155.1% | 78.59% | 67.77% | - |
| Selling, General & Admin | 3.36M | 1.93M | 28.88M | 34.9M | 39.34M | 31.25M | 18.14M | 12.62M | 11.43M | 8.7M |
| SG&A % of Revenue | 75.06% | 22.92% | 122.09% | 83.32% | 88.44% | 88.27% | 75.11% | 64.79% | 59.58% | - |
| Research & Development | 0 | 0 | 0 | 424.45K | 1.42M | 633.39K | 173.04K | 39.02K | 0 | 24.59K |
| R&D % of Revenue | - | - | - | 1.01% | 3.2% | 1.79% | 0.72% | 0.2% | - | - |
| Other Operating Expenses | 0 | 5.63M | 0 | 9.05M | 8.84M | 7.67M | 7.52M | 2.65M | 1.57M | 1.79M |
| Operating Income | -239.29K▲ 0% | 117.1K▲ 148.9% | 19.14M▲ 16247.9% | -17.58M▼ 191.8% | -19.62M▼ 11.6% | 35.81M▲ 282.5% | -9.27M▼ 125.9% | -3.19M▲ 65.6% | -2.16M▲ 32.2% | -288.36M▲ 0% |
| Operating Margin % | -5.35% | 1.39% | 80.94% | -41.98% | -44.1% | 101.14% | -38.37% | -16.37% | -11.27% | -5.73% |
| Operating Income Growth % | 93.59% | 148.94% | 16247.89% | -191.84% | -11.57% | 282.54% | -125.88% | 65.59% | 32.2% | - |
| EBITDA | -168.01K | 339.64K | 19.43M | -15.68M | -17.36M | 38.78M | -6.34M | -1.37M | -366.67K | -286.49M |
| EBITDA Margin % | -3.75% | 4.03% | 82.16% | -37.44% | -39.03% | 109.53% | -26.25% | -7.03% | -1.91% | -5.69% |
| EBITDA Growth % | 95.44% | 302.15% | 5621.5% | -180.69% | -10.72% | 323.34% | -116.35% | 78.41% | 73.22% | -38077.56% |
| D&A (Non-Cash Add-back) | 71.28K | 222.55K | 289.57K | 1.9M | 2.25M | 2.97M | 2.93M | 1.82M | 1.8M | 1.87M |
| EBIT | -860.54K | 355.08K | -14.36M | -17.58M | -24.26M | -17.31M | -9.27M | -3.32M | -2.16M | -2.24M |
| Net Interest Income | -500.63K | -955 | 75.07K | 39.88K | -28.93K | 16.25K | 63.7K | -29.51K | 34.31K | 26.06K |
| Interest Income | 0 | 0 | 75.07K | 39.88K | 0 | 16.25K | 63.7K | 0 | 34.31K | 26.06K |
| Interest Expense | 500.63K | 955 | 0 | 0 | 28.93K | 0 | 0 | 29.51K | 0 | 0 |
| Other Income/Expense | -1.12M | 0 | -32.99M | 28.89M | -4.67M | -52.77M | -13.67M | -510.55K | 121.69K | 3.18M |
| Pretax Income | -1.36M▲ 0% | 46.83K▲ 103.4% | -47.79M▼ 102138.6% | 11.31M▲ 123.7% | -24.29M▼ 314.8% | -70.08M▼ 188.5% | -22.94M▲ 67.3% | -3.7M▲ 83.9% | -2.04M▲ 44.8% | -285.19M▲ 0% |
| Pretax Margin % | -30.42% | 0.56% | -202.05% | 26.99% | -54.61% | -197.96% | -94.96% | -18.99% | -10.63% | -1519.43% |
| Income Tax | 25K | -16K | -2.36M | -1.35M | -895K | 0 | 0 | 0 | 0 | 41.47M |
| Effective Tax Rate % | -1.84% | -34.16% | 4.94% | -11.9% | 3.68% | 0% | 0% | 0% | 0% | -14.54% |
| Net Income | -1.74M▲ 0% | -412.07K▲ 76.3% | -45.43M▼ 10924.6% | 12.6M▲ 127.7% | -23.39M▼ 285.6% | -74.09M▼ 216.7% | -22.94M▲ 69.0% | -3.7M▲ 83.9% | -2.04M▲ 44.8% | -327.66M▲ 0% |
| Net Margin % | -38.85% | -4.89% | -192.08% | 30.09% | -52.6% | -209.26% | -94.96% | -18.99% | -10.63% | -6.51% |
| Net Income Growth % | 48.2% | 76.3% | -10924.64% | 127.74% | -285.64% | -216.67% | 69.04% | 83.87% | 44.84% | -12087.28% |
| Net Income (Continuing) | -1.39M | -1.8M | -45.43M | 12.65M | -23.39M | -70.08M | -22.94M | -3.7M | -2.04M | -326.66M |
| Discontinued Operations | 0 | 0 | 0 | -48.98K | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 937.06K | 1.41M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -10.44▲ 0% | -2.39▲ 77.1% | -114.29▼ 4682.0% | 12.19▲ 110.7% | -19.16▼ 257.2% | -55.80▼ 191.2% | -13.32▲ 76.1% | -1.79▲ 86.6% | -1.09▲ 39.1% | -36.39▲ 0% |
| EPS Growth % | 71.46% | 77.11% | -4682.01% | 110.67% | -257.18% | -191.23% | 76.13% | 86.56% | 39.11% | -1011.1% |
| EPS (Basic) | -10.44 | -2.39 | -114.29 | 12.47 | -19.16 | -55.80 | -13.32 | -1.79 | -1.09 | - |
| Diluted Shares Outstanding | 166.49K | 172.22K | 397.49K | 1M | 1.22M | 1.33M | 2.02M | 4.31M | 4.02M | 9M |
| Basic Shares Outstanding | 166.49K | 172.06K | 397.49K | 980.9K | 1.22M | 1.33M | 2.02M | 4.31M | 4.02M | 9M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
YCBD Balance Sheet
cbdMD, Inc. (YCBD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.69M | 11.79M | 15.74M | 23.71M | 36.5M | 16.01M | 8.07M | 6.39M | 6.55M | 8.17M |
| Cash & Short-Term Investments | 1.14M | 6.49M | 5.49M | 15.1M | 27.44M | 7.72M | 1.8M | 2.45M | 2.26M | 3.39M |
| Cash Only | 284.25K | 4.28M | 4.69M | 14.82M | 26.41M | 6.72M | 1.8M | 2.45M | 2.26M | 3.39M |
| Short-Term Investments | 859.11K | 2.21M | 798.54K | 276.47K | 1.03M | 1M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.38M | 4.2M | 2.67M | 911.48K | 1.11M | 1.45M | 1.22M | 983.91K | 1.04M | 1.12M |
| Days Sales Outstanding | 112.48 | 182.27 | 41.14 | 7.94 | 9.14 | 14.93 | 18.38 | 18.43 | 19.8 | 20.31 |
| Inventory | 588.2K | 123.22K | 4.3M | 4.89M | 5.02M | 4.26M | 4.05M | 2.37M | 0 | 0 |
| Days Inventory Outstanding | 158.4 | 16.82 | 171.84 | 115.08 | 126.46 | 118.88 | 161.19 | 115.31 | - | 0.37 |
| Other Current Assets | 583.15K | 589.54K | 1.3M | 1.39M | 1.16M | 703.32K | 750.38K | 406.67K | 3.25M | 3.66M |
| Total Non-Current Assets | 3.38M | 3.23M | 78.78M | 87.13M | 88.38M | 24.78M | 8.13M | 4.19M | 3.87M | 3.62M |
| Property, Plant & Equipment | 135.48K | 53.48K | 2.47M | 10.83M | 8.71M | 5.55M | 4.07M | 602.79K | 1.04M | 920.76K |
| Fixed Asset Turnover | 33.03x | 157.44x | 9.58x | 3.87x | 5.11x | 6.38x | 5.94x | 32.32x | 18.38x | 15.69x |
| Goodwill | 0 | 0 | 54.67M | 54.67M | 56.67M | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 3.24M | 3.17M | 21.64M | 21.64M | 23.12M | 17.83M | 3.22M | 2.89M | 2.12M | 1.93M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 1.4M | 700K | 700K | 700K | 2.8M |
| Other Non-Current Assets | -2.44B | 0 | 0 | 0 | -114.18K | 1.64B | 138.71K | 0 | 0 | 62.71K |
| Total Assets | 7.07M▲ 0% | 15.02M▲ 112.4% | 94.52M▲ 529.4% | 110.84M▲ 17.3% | 124.88M▲ 12.7% | 40.79M▼ 67.3% | 16.2M▼ 60.3% | 10.58M▼ 34.7% | 10.42M▼ 1.5% | 11.78M▲ 0% |
| Asset Turnover | 0.63x | 0.56x | 0.25x | 0.38x | 0.36x | 0.87x | 1.49x | 1.84x | 1.84x | 1.74x |
| Asset Growth % | 335.48% | 112.43% | 529.38% | 17.27% | 12.67% | -67.34% | -60.3% | -34.66% | -1.53% | -52.8% |
| Total Current Liabilities | 1.52M | 969.96K | 3.71M | 7.69M | 6.92M | 5.29M | 4.67M | 8.62M | 3.19M | 2.77B |
| Accounts Payable | 465.48K | 481.58K | 3.02M | 2.85M | 2.98M | 2.04M | 1.91M | 1.54M | 1.17M | 880.98M |
| Days Payables Outstanding | 125.35 | 65.75 | 120.7 | 67.06 | 75.01 | 56.89 | 75.81 | 75.13 | 51.31 | 39.92 |
| Short-Term Debt | 0 | 0 | 0 | 909.64K | 59.47K | 9.61K | 2.49K | 1.17M | 778.24M | 593.03M |
| Deferred Revenue (Current) | 41.42K | 161.46K | 7.34K | 45.14K | 0 | 0 | 185.25K | 503.25K | 506.29M | 490.2M |
| Other Current Liabilities | 0 | 0 | 0 | 864.5K | 0 | 0 | 0 | 0 | -1.28B | 811.53M |
| Current Ratio | 2.42x | 12.16x | 4.24x | 3.08x | 5.28x | 3.03x | 1.73x | 0.74x | 2.05x | 2.05x |
| Quick Ratio | 2.04x | 12.03x | 3.08x | 2.45x | 4.55x | 2.22x | 0.86x | 0.47x | 2.05x | 2.05x |
| Cash Conversion Cycle | 145.52 | 133.34 | 92.29 | 55.96 | 60.58 | 76.92 | 103.75 | 58.61 | - | -19.24 |
| Total Non-Current Liabilities | 397K | 28.5K | 53.2M | 23.97M | 14.82M | 4.08M | 2.49M | 0 | 0 | 0 |
| Long-Term Debt | 360K | 0 | 0 | 602.1K | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 6.01M | 4.86M | 3.68M | 2.4M | 0 | 0 | 601.38K |
| Deferred Tax Liabilities | 37K | 21K | 2.24M | 895K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 7.5K | 50.96M | 16.46M | 9.96M | 401.49K | 90.37K | 0 | 0 | 0 |
| Total Liabilities | 1.92M | 998.46K | 56.91M | 31.66M | 21.74M | 9.37M | 7.16M | 8.62M | 3.19M | 2.77B |
| Total Debt | 360K | 0 | 194.47K | 8.68M | 6.07M | 4.87M | 3.68M | 1.27M | 778.24M | 593.03M |
| Net Debt | 75.75K | -4.28M | -4.5M | -6.14M | -20.34M | -1.85M | 1.89M | -1.18M | 775.98M | 589.64M |
| Debt / Equity | 0.07x | - | 0.01x | 0.11x | 0.06x | 0.15x | 0.41x | 0.65x | 107.70x | 107.70x |
| Debt / EBITDA | - | - | 0.01x | - | - | 0.13x | - | - | - | -2.07x |
| Net Debt / EBITDA | - | -12.61x | -0.23x | - | - | -0.05x | - | - | - | -2.06x |
| Interest Coverage | -0.48x | 122.62x | - | - | -678.05x | - | - | -108.10x | - | - |
| Total Equity | 5.15M▲ 0% | 14.02M▲ 172.3% | 37.6M▲ 168.2% | 79.18M▲ 110.6% | 103.14M▲ 30.3% | 31.42M▼ 69.5% | 9.03M▼ 71.3% | 1.96M▼ 78.3% | 7.23M▲ 268.0% | 9.01B▲ 0% |
| Equity Growth % | 1858.96% | 172.27% | 168.23% | 110.57% | 30.26% | -69.53% | -71.26% | -78.26% | 268.04% | 505804.98% |
| Book Value per Share | 30.93 | 81.40 | 94.60 | 78.88 | 84.48 | 23.67 | 4.47 | 0.46 | 1.80 | 1000.45 |
| Total Shareholders' Equity | 4.21M | 12.61M | 37.6M | 79.18M | 103.14M | 31.42M | 9.03M | 1.96M | 7.23M | 9.01B |
| Common Stock | 5.79K | 8.12K | 27.72K | 52.13K | 57.78K | 60.67K | 2.96K | 3.94K | 8.92K | 10.07K |
| Retained Earnings | -6.26M | -6.67M | -59.61M | -47.39M | -73.34M | -147.42M | -174.36M | -182.07M | -179.44M | -179.76B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -2.51M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 937.06K | 1.41M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
YCBD Cash Flow Statement
cbdMD, Inc. (YCBD) cash flow — operating, investing & free cash flow history
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.33M | -5.57M | -15.38M | -10.66M | -14.09M | -14.97M | -4.3M | -352.79K | -1.45M | -1.45M |
| Operating CF Margin % | -52.06% | -66.19% | -65.02% | -25.46% | -31.68% | -42.28% | -17.81% | -1.81% | -7.57% | - |
| Operating CF Growth % | 19.58% | -139.21% | -175.92% | 30.65% | -32.15% | -6.2% | 71.26% | 91.8% | -311.68% | -669.29% |
| Net Income | -1.39M | 62.83K | -51.36M | 12.6M | -23.39M | -70.08M | -22.94M | -3.7M | -2.04B | -327.66M |
| Depreciation & Amortization | 71.28K | 222.55K | 289.57K | 720.75K | 2.25M | 2.97M | 2.93M | 1.82M | 1.13B | 829.89M |
| Stock-Based Compensation | 212.93K | 678.73K | 2.69M | 2.04M | 2.92M | 928.83K | 342.87K | 16.9K | 0 | 11.25K |
| Deferred Taxes | 296.23K | 571.65K | 6.79M | 1.21M | -471.02K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -239.45K | -2.91M | 32.28M | -27.05M | 7.42M | 53.99M | 14.8M | 2.05M | 915.28M | -79.21M |
| Working Capital Changes | -988.43K | -4.2M | -6.07M | -184.51K | -2.82M | -2.77M | 570.45K | -538.83K | -1.97M | -2.25M |
| Change in Receivables | -789.99K | -991.95K | -401.98K | 514.35K | -183.74K | 65.54K | 278.48K | 232.18K | -439.56K | -227.38K |
| Change in Inventory | -41.22K | 255.89K | -3.12M | -535.15K | -1.01M | -112.19K | 27.44K | 790.14K | -788.71K | -1.29M |
| Change in Payables | -466.99K | -666.67K | 394.32K | 1.48M | -740.07K | -1.81M | 61.18K | -1.12M | -261.88K | -302.06K |
| Cash from Investing | 152.31K | -683.56K | -2.13M | -1.57M | -2.55M | -688.68K | 702.45K | -290.01K | -184.17K | -164.82M |
| Capital Expenditures | -7.97K | -383.56K | -1.25M | -1.32M | -2.34M | -688.68K | -297.55K | -290.01K | -184.17M | -344.53M |
| CapEx % of Revenue | 0.18% | 4.56% | 5.28% | 3.15% | 5.27% | 1.95% | 1.23% | 1.49% | 959.71% | - |
| Acquisitions | 0 | 0 | -916.55K | 0 | 2M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -39.72K | -660K | 31.32K | -250K | -2M | 0 | 0 | 0 | 183.99M | 179.71M |
| Cash from Financing | 2.43M | 10.25M | 17.92M | 22.37M | 28.23M | -4.04M | -1.32M | 1.3M | 1.45M | 3.55M |
| Debt Issued (Net) | 1.62M | 0 | -764.3K | 1.49M | -151.55K | -33.35K | -132.6K | 1.25M | 0 | 0 |
| Equity Issued (Net) | 829.5K | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 50K | 1000K | 2M |
| Dividends Paid | -29.18K | 0 | 0 | -366.85K | -2.55M | -4M | -3.67M | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -30.79M | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 3K | -672.57K | -326.87K | 62.2K | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 249.99K▲ 0% | 4M▲ 1499.4% | 407.41K▼ 89.8% | 10.13M▲ 2387.6% | 11.59M▲ 14.3% | -19.69M▼ 269.9% | -4.92M▲ 75.0% | 654.69K▲ 113.3% | -191.31K▼ 129.2% | 1.13B▲ 0% |
| Free Cash Flow | -2.34M▲ 0% | -5.96M▼ 154.8% | -16.63M▼ 179.1% | -11.98M▲ 27.9% | -16.44M▼ 37.1% | -15.66M▲ 4.7% | -4.6M▲ 70.6% | -642.81K▲ 86.0% | -1.64M▼ 154.6% | -852.59M▲ 0% |
| FCF Margin % | -52.24% | -70.74% | -70.3% | -28.61% | -36.95% | -44.22% | -19.04% | -3.3% | -8.53% | -16.95% |
| FCF Growth % | 22.7% | -154.8% | -179.12% | 27.92% | -37.14% | 4.74% | 70.62% | 86.02% | -154.59% | -102051.84% |
| FCF per Share | -14.04 | -34.59 | -41.83 | -11.94 | -13.46 | -11.79 | -2.27 | -0.15 | -0.41 | -0.41 |
| FCF Conversion (FCF/Net Income) | 1.34x | 13.52x | 0.34x | -0.85x | 0.60x | 0.20x | 0.19x | 0.10x | 0.71x | 2.60x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -19.05K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
YCBD Key Ratios
cbdMD, Inc. (YCBD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -71.61% | -4.3% | -176.01% | 21.58% | -25.66% | -110.11% | -113.4% | -67.31% | -44.42% | -3.64% |
| Return on Invested Capital (ROIC) | -6.3% | 1.17% | 67.02% | -24.85% | -18.88% | 47.8% | -34.34% | -40.9% | -0.41% | -0.41% |
| Gross Margin | 69.71% | 68.25% | 61.37% | 62.96% | 67.41% | 63.09% | 62.01% | 61.57% | 56.5% | 59.8% |
| Net Margin | -38.85% | -4.89% | -192.08% | 30.09% | -52.6% | -209.26% | -94.96% | -18.99% | -10.63% | -6.51% |
| Debt / Equity | 0.07x | - | 0.01x | 0.11x | 0.06x | 0.15x | 0.41x | 0.65x | 107.70x | 107.70x |
| Interest Coverage | -0.48x | 122.62x | - | - | -678.05x | - | - | -108.10x | - | - |
| FCF Conversion | 1.34x | 13.52x | 0.34x | -0.85x | 0.60x | 0.20x | 0.19x | 0.10x | 0.71x | 2.60x |
| Revenue Growth | 120.27% | 88.16% | 180.89% | 77.09% | 6.2% | -20.41% | -31.77% | -19.35% | -1.5% | 26075.44% |
YCBD Frequently Asked Questions
cbdMD, Inc. (YCBD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
cbdMD, Inc. (YCBD) reported $18.8M in revenue for fiscal year 2025. This represents a 824% increase from $2.0M in 2016.
cbdMD, Inc. (YCBD) saw revenue decline by 1.5% over the past year.
cbdMD, Inc. (YCBD) reported a net loss of $327.7M for fiscal year 2025.
Dividend & Returns
cbdMD, Inc. (YCBD) has a return on equity (ROE) of -44.4%. Negative ROE indicates the company is unprofitable.
cbdMD, Inc. (YCBD) had negative free cash flow of $852.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More YCBD
cbdMD, Inc. (YCBD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates